Patient Education Conference on Eosinophil-Associated Diseases Comes to Washington, DC Area and Online July 11-13, 2024
July 2, 2024
EOS Connection 2024 is a hybrid conference featuring expert-led sessions and networking opportunities
(Atlanta, GA)— Patients, families, caregivers, experts, and advocates will soon gather at the 2024 EOS Connection conference, a unique event designed to facilitate the exchange of knowledge, experiences, perspectives, and needs.
Taking place July 11-13, the event offers both online and onsite participation in Bethesda, Maryland, making it accessible to all interested in learning more about eosinophil-associated diseases. This year marks the 22nd year that the American Partnership for Eosinophilic Disorders (APFED) has hosted this annual patient education conference for families living with these conditions.
Collaborating on this year’s EOS Connection conference is the Children’s Hospital of Philadelphia’s Center for Pediatric Eosinophilic Disorders, the Consortium of Eosinophilic Gastrointestinal Disease Researchers, Mount Sinai Center for Eosinophilic Disorders at the Icahn School of Medicine in New York City, and the Multidisciplinary Eosinophilic GI Disease Clinic at University of Virginia.
Eosinophil-associated diseases are chronic inflammatory conditions characterized by elevated levels of eosinophils (a type of white blood cell) in one or more specific areas of the body. The elevated number of eosinophils causes inflammation and damage to surrounding tissues and organs. These conditions require lifelong medical care and symptoms can be debilitating.
The conference will provide a patient-centered program that highlights important information in the clinical and research areas. Attendees will learn the latest advancements in the diagnosis and treatment of eosinophil-associated diseases, research updates, and practical strategies to help people better manage their condition. The conference also provides social opportunities for families and special programming for children and teens who attend onsite.
“APFED strives to empower patients and families affected by eosinophil-associated diseases through education, support, and advocacy,” said APFED Executive Director Mary Jo Strobel. “EOS Connection provides a vital platform for sharing the latest advancements and fostering a strong, supportive community. We are excited to offer both onsite and virtual participation options this year, ensuring that everyone has the opportunity to participate and engage.”
APFED is working with a number of Education Partners, including Sanofi, Regeneron, and Takeda, to bring this opportunity to patients and families.
“We’re proud to partner again with the APFED for the EOS Connection Patient Conference,” said Piya Sircar, US Head of Rhinology, Gastroenterology, & Allergy at Sanofi. “The conference not only provides valuable education and resources but also fosters a sense of unity and collaboration within the patient community.”
“Sponsoring this important patient conference aligns with our commitment to patients and research into eosinophilic esophagitis and other eosinophil-associated diseases,” said Amr Radwan, Executive Director of Global Medical Affairs for Immunology and Inflammation at Regeneron. “We thank APFED for their ongoing advocacy and education efforts, and we are looking forward to the incredible conference program ahead.”
“We believe in the power of community and knowledge-sharing, which is why we are delighted to support the EOS Connection Conference in bringing together patients, their families and healthcare professionals to gain a deeper understanding of eosinophil-associated diseases and advancements in patient care,” said Jackie Henze, vice president, head of the GI Rare Franchise and New Product Launches, Takeda.
Other Education Partners supporting in the event include but are not limited to AstraZeneca, Ellodi Pharmaceutical, Bristol Myers Squibb™, and Reckitt Mead Johnson Nutrition.
To learn more and register for EOS Connection 2024, please visit: apfed.org/conference.
About the American Partnership for Eosinophilic Disorders (APFED)
The American Partnership for Eosinophilic Disorders (APFED) is a non-profit organization whose mission is to passionately embrace, support, and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support, and advocacy. https://www.APFED.org
###